Results 31 to 40 of about 38,820 (264)

Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

Case Reports in Gastrointestinal Medicine, 2019
We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of ...
Matthew H. Kemm, Cory D. Manly, Thanh D. Hoang, Vinh Q. Mai, Mohamed K. M. Shakir   +4 more
doaj   +1 more source

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

Cellular Physiology and Biochemistry, 2018
Background/Aims: Hepatocellular carcinoma (HCC) is a major threat to human health. The condition carries a high risk of death; 45% of new cases occur in China.
Chuan-Zhong Huang, Ai-Min Huang, Jing-Feng Liu, Bin Wang, Ke-Can Lin, Yun-Bin Ye   +5 more
doaj   +1 more source

Necrotizing enterocolitis as a side effect of octreotide in a preterm neonate, a case report

Journal of Pediatric Surgery Case Reports, 2022
Congenital chylous ascites (CCA) is a rare disease, characterized by accumulation of chyle in the peritoneal cavity in infants
Nasim Rabiee, Ava Navidi Moghaddam, Naeeme Taslimi Taleghani, Shahrzad Tabatabaee, Farzaneh Palizban, Minoo Fallahi   +5 more
doaj  

Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]

PLoS ONE, 2012
BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melmed   +5 more
doaj   +1 more source

Octreotide Use in Neonates: A Case Series

Drugs in R&D, 2018
Background and ObjectiveOctreotide is a somatostatin analogue and has been used off-label for a variety of conditions. There are no specific guidelines for the use of octreotide in neonates and its safety and efficacy have not been systematically ...
Syed Ahmed Zaki, Mohan B. Krishnamurthy, A. Malhotra   +2 more
semanticscholar   +1 more source

Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors

Бюллетень сибирской медицины, 2019
Currently the development of technologies for labeling somatostatin with technetium-99m for diagnosing radionuclide neuroendocrine tumors is under way. Somatostatin analogues are binded with technetium99m only by the preliminary addition of a chelating ...
M. S. Larkina, E. V. Podrezova, O. D. Bragina, E. A. Tagirova, V. I. Chernov, M. S. Yusubov, E. A. Nesterov, V. S. Skuridin, S. V. Krivoshchekov, E. A. Yanovskaya, R. V. Gurto, M. V. Belousov   +11 more
doaj   +1 more source

Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China

Pediatric Investigation, 2020
Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao, Wu Di, Chang Su, Jiajia Chen, Xuejun Liang, Min Liu, Wenjing Li, Xiaoqiao Li, Chunxiu Gong   +8 more
doaj   +1 more source

Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors

Oncology Letters, 2017
Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is known to overexpress somatostatin receptors (SSTRs), most commonly SSTR2 and SSTR5. The expression of SSTRs on tumor cells forms the basis for somatostatin analog treatment of patients with NEN.
Yu-hong Wang, Wei Wang, K. Jin, Cheng Fang, Yuan Lin, L. Xue, S. Feng, Zhiwei Zhou, C. Shao, Minhu Chen, Xianjun Yu, Jie Chen   +11 more
semanticscholar   +1 more source

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.

Journal of Neurosurgery, 2017
OBJECTIVE Meningiomas express somatostatin receptor subtype 2 (SST2), which is targeted by the somatostatin analog octreotide. However, to date, using somatostatin analog therapy for the treatment of these tumors in clinical practice has been debated ...
T. Graillon, D. Romano, Céline Défilles, A. Saveanu, A. Mohamed, D. Figarella-Branger, P. Roche, S. Fuentes, O. Chinot, H. Dufour, A. Barlier   +10 more
semanticscholar   +1 more source

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source